GLA

LY2228820 : A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

AZD1390 : Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs

Epinephrine bitartrate : Expired Epinephrine Maintains Chemical Concentration and Sterility

Bisindolylmaleimide IX : Bisindolylmaleimide IX facilitates extrinsic and initiates intrinsic apoptosis in TNF-a-resistant human colon adenocarcinoma COLO 205 cells

TAPI-1 : GRO-α/CXCR2 System and ADAM17 Correlated Expression in Sjögren’s Syndrome

SEL120-34A : p27 and Leukemia: Cell Cycle and Beyond

SAHA : Sustainable space for a sustainable Earth? Circular economy insights from the space sector